Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Accent Therapeutics
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06625515CT.gov First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rectum Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Atx-559 (this asset) | Accent Therapeutics | P1 | C · 39 |
| Fluorouracilum | Merck Sharp & Dohme LLC | P3 | BBB |
| Irinotecan | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | BBB |
| Cetuximab | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | BB |
| Oxaliplatin | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | BB |
| Pertuzumab | SWOG Cancer Research Network | P2 | BB |
| Regorafenib | City of Hope Medical Center | P2 | BB |
| Tipiracil | Sir Run Run Shaw Hospital | P2 | BB |
| Trifluridine | Sir Run Run Shaw Hospital | P2 | BB |
+42 more in the Rectum Adenocarcinoma cohort
Other indications for Atx-559
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P1 | CC · 43 |
| Metastatic Malignant Neoplasm In The Colon | — | P1 | C · 37 |
| Colon Carcinoma | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Atx-559 in Rectum Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/atx-559-rectum-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →